a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

Application Number		10647068		
Filing Date		2003-08-22		
First Named Inventor	Argen	nta, et al.		
Art Unit		3733		
Examiner Name	PHIL	DGENE, PEDRO		
Attorney Docket Numb	er	0101-2977US1		

				U.S.	PATENTS	Remove
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear
	1	4969880		1990-11-13	Zamierowski	
	2	5100396		1992-03-31	Zamierowski	
	3	5261893		1993-11-16	Zamierowski	
	4	5527293		1996-06-18	Zamierowski	
	5	6071267		2000-06-06	Zamierowski	
	6	6117111		2000-09-12	Fleischmann	
	7	6135116		2000-10-24	Vogel	
	8	6142982		2000-11-07	Hunt	

9	6174306	2001-01-16	Fleischmann	
10	6345623	2002-02-12	Heaton	
11	6398767	2002-06-04	Fleischmann	
12	6491693	2002-12-10	M. Lytinas	
13	6520982	2003-02-18	Boynton	
14	6553998	2003-04-29	Heaton	
15	6648862	2003-11-18	R. Watson	
16	6695823	2004-02-24	C.Z. Lina	
17	6767334	2004-07-27	L.T. Randolph	
18	6814079	2004-11-09	Heaton	
19	6856821	2005-02-15	R. Johnson	

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		10647068		
	Filing Date		2003-08-22		
	First Named Inventor	Argen	nta, et al.		
	Art Unit  Examiner Name PHILO  Attorney Docket Number		3733		
			OGENE, PEDRO		
			0101-2977US1		

	20	6936037		2005-08-30	Bubb	
	21	6951553		2005-10-04	Bubb	
	22	6994702		2006-02-07	R.W. Johnson	
	23	7004915		2006-02-28	T.A. Boynton	
	24	7070584		2006-07-04	Johnson	
	25	7077832		2006-07-18	Floischmann	
	26	7108683		2006-09-19	Zamierowski	
	27	7117869		2006-10-10	Heaton	
	28	7144390		2006-12-05	R.R. Hannigan	
	29	7169151		2007-01-30	M. Lytinas	
If you wish	h to a	dd additional U.S. Paten			lease click the Add button.	Add
			U.S.P	ATENT APPLI	CATION PUBLICATIONS	Remove

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

	Application Number Filing Date		10647068		
			2003-08-22		
	First Named Inventor	Argen	nta, et al.		
	Art Unit		3733		
	Examiner Name	PHIL	OGENE, PEDRO		
	Attomory Docket Number		0101-2977US1		

Examiner Initial*	aminer Cite No Publication Number Kind Code <sup>1</sup> Date		ition	Name or Patentee or Applicant Rel			es,Columns,Lines where evant Passages or Relevant ures Appear				
	1										
If you wis	h to a	dd additional U.S. Publ						d butto			_
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Countr Code <sup>2</sup>	y	Kind Code4	Publication Date	Name of Patente Applicant of cited Document		Pages,Columns, where Relevant Passages or Rele Figures Appear	-	Ţ5
	1	0777504	EP			1997-06-11	C.Z. Lina				
	2	0853950	EP			1998-07-22	C.Z. Lina				
	3	1088569	EP			2001-04-04	K.M. Hunt				
	4	2329127	GB			1999-03-17	K.P. Heaton				
	5	2333965	GB			1999-08-11	K.P. Heaton				
	6	2336546	GB			1999-10-27	K.P. Healon				
	7	2342584	GB			2000-04-19	K.P. Heaton				_

	Application Number		10647068	
	Filing Date		2003-08-22	
INFORMATION DISCLOSURE	First Named Inventor	Argen	nta, et al.	
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		3733	
(Not for Submission under or or it issue	Examiner Name	PHIL	OGENE, PEDRO	
	Attorney Docket Numb	er	0101-2977US1	

	8	2344531	GB	2000-06-14	K.P. Heaton	
	9	2351025	GB	2000-12-20	K.P. Heaton	
	10	00/21586	wo	2000-04-20	K.W. Hunt	
	11	00/38755	wo	2000-07-06	L.T. Randolph	
	12	00/59418	wo	2000-10-12	R.R. Hannigan	
	13	00/59424	wo	2000-10-12	R.W. Royce	
	14	00/61206	wo	2000-10-19	C.Z. Lina	
	15	00/64394	wo	2000-11-02	KP. Heaton	
	16	01/34223	wo	2001-05-17	KP. Heaton	
	17	01/85248	wo	2001-11-15	K.W. Hunt	
	18	96/05873	wo	1996-02-29	C.Z. Lina	

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

Application Number		10647068			
Filing Date		2003-08-22			
First Named Inventor	Argenta, et al.				
Art Unit		3733			
Examiner Name	PHILOGENE, PEDRO				
Attorney Docket Numb	er	0101-2977US1			

	19	99/13793	wo		1999-03-25	K.P. Heaton		_	
If you wis	h to a	dd additional Foreign I	Patent Document	citation	information pl	lease click the Add butto	n Add		
			NON-PATE	NT LITE	RATURE DO	CUMENTS	Remove		
Examiner Initials*	Examiner Cite Initials* Cite Cook, agazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.							Τs	
	1								
If you wis	h to a	dd additional non-pate	nt literature docu	ment ci	tation informat	ion please click the Add	button Add		
			EX	AMINE	R SIGNATUR	E			
Examiner	Examiner Signature Date Considered								
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a									

Fi

Б

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04, 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the sensi number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language translation is attached.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

Application Number		10647068		
Filing Date		2003-08-22		
First Named Inventor	Argenta, et al.			
Art Unit		3733		
Examiner Name	PHIL	OGENE, PEDRO		
Attorney Docket Number		0101-2977US1		

#### CERTIFICATION STATEMENT

Please see	37	CFR .	97	and	1 02	to	make the	annror	viote	بمامه	tion	ſ٥١	ŀ

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 97.0F4.137(e)(1).

### OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(e).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Niels Haurr/	Date (YYYY-MM-DD)	2007-04-23
Name/Print	Niels Haun	Registration Number	48 488

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenary Cfing. U.S. Operatment of Commence, P. 0. Box 1450, Alexandria, V.S. 2313-1450. D. ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2313-1450.

### Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the stacked form related to a petient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is civulating; and (3) the principal purpuse for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or cosmisting your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or cosmisting your submission related to a patient agricultant or patient. If you do not furnish the requested process and the process of the process and the process of the pro

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record perfains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
  application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
  disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
  which became abandoned or in which the proceedings were terminated and which application is referenced by either a
  published application, an application open to public inspections or as issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.